EgiliusL. H.SpieringsMD

Headache

Medical Director, Greater Boston Headache Center, Boston Advanced Medicine, Waltham, Massachusetts; Retired Clinical Professor of Neurology and Craniofacial Pain, Tufts University Schools of Medicine and Dental Medicine; Former Associate Clinical Professor of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Join to view full profile

Dr. Spierings is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spierings' full profile

Already have an account?

Office
85 First Avenue
Waltham, MA 02452
Phone+1 617-744-1310

Fax+1 617-744-1285

Summary

Dr. Egilius Spierings is a neurologist in Waltham, MA. He received his medical degree from Erasmus University Rotterdam Faculty of Medicine and has been in practice 39 years. He also speaks Dutch. He specializes in headache and face pain and is experienced in clinical-trial research. He has more than 100 publications and over 500 citings.

Education & Training

Faculty of Medicine, Erasmus University, RotterdamPhD, Pharmacology, 1978 - 1980
Erasmus University Rotterdam Faculty of MedicineClass of 1978

Certifications & Licensure

MA State Medical License 1987 - 2025
Royal Netherlands Medical Association (Neurology), 1986; Board of Registration in Medicine, Commonwealth of Massachusetts, 1986

Clinical Trials

Staccato Loxapine in Migraine (in Clinic) Start of enrollment: 2007 Jun 01
Completed
Phase 2
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone Start of enrollment: 2007 Aug 01
Completed
Phase 3
Staccato Prochlorperazine in Migraine (in Clinic) Start of enrollment: 2005 Mar 01
Completed
Phase 2
Treatment of Insomnia in Migraineurs Start of enrollment: 2007 Apr 01
Completed
Phase 4
Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning Start of enrollment: 2009 May 01
Completed
Phase 4
Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache Start of enrollment: 2009 Nov 01
Completed
Not Applicable
Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Start of enrollment: 2012 Dec 01
Unknown status
Phase 4
Join now to see all

Publications & Presentations

PubMed

199 citations
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal, Lars Edvinsson, Alan M. Rapoport, Richard B. Lipton, Egilius L.H. Spierings
The Lancet. Neurology. 2015-11-01
269 citations
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placeb...
David W. Dodick, Peter J. Goadsby, Egilius L.H. Spierings, Joel C Scherer, Steven Sweeney
The Lancet. Neurology. 2014-09-01
6 citations
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled st...
Timothy R. Smith, Egilius L.H. Spierings, Roger Cady, Joe Hirman, Anders Ettrup
The Journal of Headache and Pain. 2021-11-25

Press Mentions

Alder BioPharmaceuticals® to Present New Data Further Highlighting Eptinezumab's Efficacy Profile for Migraine Prevention at American Headache Society MeetingJune 20th, 2018
Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain FreedomJune 12th, 2017